Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.